Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals

Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from...

Full description

Saved in:
Bibliographic Details
Published inJournal of Virology Vol. 85; no. 21; pp. 11502 - 11519
Main Authors Tomaras, Georgia D., Binley, James M., Gray, Elin S., Crooks, Emma T., Osawa, Keiko, Moore, Penny L., Tumba, Nancy, Tong, Tommy, Shen, Xiaoying, Yates, Nicole L., Decker, Julie, Wibmer, Constantinos Kurt, Gao, Feng, Alam, S. Munir, Easterbrook, Philippa, Abdool Karim, Salim, Kamanga, Gift, Crump, John A., Cohen, Myron, Shaw, George M., Mascola, John R., Haynes, Barton F., Montefiori, David C., Morris, Lynn
Format Journal Article
LanguageEnglish
Published Washington, DC American Society for Microbiology 01.11.2011
Subjects
Antibodies, Neutralizing - blood
B-Lymphocytes - immunology
Biological and medical sciences
Epitopes, B-Lymphocyte - immunology
Fundamental and applied biological sciences. Psychology
HIV Antibodies - blood
HIV Envelope Protein gp120 - immunology
HIV Envelope Protein gp41 - immunology
HIV Infections - immunology
HIV-1 - immunology
Humans
Microbiology
Miscellaneous
Pathogenesis and Immunity
Virology
Infection
Immunopathology
Antigenic determinant
Viral disease
AIDS
B-Lymphocyte
Immune deficiency
Neutralizing antibody
Online AccessGet full text
ISSN0022-538X
1098-5514
1098-5514
DOI10.1128/JVI.05363-11

Cover

Abstract Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
AbstractList A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a multiclade panel of 12 "tier 2" viruses (4 each of subtypes A, B, and C). Various neutralizing epitope specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein.A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a multiclade panel of 12 "tier 2" viruses (4 each of subtypes A, B, and C). Various neutralizing epitope specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein.
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a multiclade panel of 12 “tier 2” viruses (4 each of subtypes A, B, and C). Various neutralizing epitope specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein.
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
Author Myron Cohen
Xiaoying Shen
George M. Shaw
Georgia D. Tomaras
Elin S. Gray
Tommy Tong
Gift Kamanga
Julie Decker
David C. Montefiori
John R. Mascola
Barton F. Haynes
Philippa Easterbrook
Emma T. Crooks
James M. Binley
Nicole L. Yates
Salim Abdool Karim
Constantinos Kurt Wibmer
S. Munir Alam
Feng Gao
John A. Crump
Keiko Osawa
Lynn Morris
Penny L. Moore
Nancy Tumba
Author_xml – sequence: 1
  givenname: Georgia D.
  surname: Tomaras
  fullname: Tomaras, Georgia D.
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 2
  givenname: James M.
  surname: Binley
  fullname: Binley, James M.
  organization: Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121
– sequence: 3
  givenname: Elin S.
  surname: Gray
  fullname: Gray, Elin S.
  organization: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg
– sequence: 4
  givenname: Emma T.
  surname: Crooks
  fullname: Crooks, Emma T.
  organization: Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121
– sequence: 5
  givenname: Keiko
  surname: Osawa
  fullname: Osawa, Keiko
  organization: Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121
– sequence: 6
  givenname: Penny L.
  surname: Moore
  fullname: Moore, Penny L.
  organization: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg
– sequence: 7
  givenname: Nancy
  surname: Tumba
  fullname: Tumba, Nancy
  organization: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg
– sequence: 8
  givenname: Tommy
  surname: Tong
  fullname: Tong, Tommy
  organization: Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121
– sequence: 9
  givenname: Xiaoying
  surname: Shen
  fullname: Shen, Xiaoying
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 10
  givenname: Nicole L.
  surname: Yates
  fullname: Yates, Nicole L.
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 11
  givenname: Julie
  surname: Decker
  fullname: Decker, Julie
  organization: Kings College London School of Medicine and Dentistry, Western Education Centre, 10 Cutcombe Road, London SE5 9RJ, United Kingdom
– sequence: 12
  givenname: Constantinos Kurt
  surname: Wibmer
  fullname: Wibmer, Constantinos Kurt
  organization: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg
– sequence: 13
  givenname: Feng
  surname: Gao
  fullname: Gao, Feng
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 14
  givenname: S. Munir
  surname: Alam
  fullname: Alam, S. Munir
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 15
  givenname: Philippa
  surname: Easterbrook
  fullname: Easterbrook, Philippa
  organization: Kings College London School of Medicine and Dentistry, Western Education Centre, 10 Cutcombe Road, London SE5 9RJ, United Kingdom
– sequence: 16
  givenname: Salim
  surname: Abdool Karim
  fullname: Abdool Karim, Salim
  organization: University of KwaZulu-Natal, Private Bag X7, Congella, Durban, KwaZulu-Natal 4013, South Africa
– sequence: 17
  givenname: Gift
  surname: Kamanga
  fullname: Kamanga, Gift
  organization: Tidziwe Centre, Kamuzu Central Hospital, Lilongwe, Malawi
– sequence: 18
  givenname: John A.
  surname: Crump
  fullname: Crump, John A.
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, Kilimanjaro Christian Medical Centre, P.O. Box 3010, Moshi, Tanzania
– sequence: 19
  givenname: Myron
  surname: Cohen
  fullname: Cohen, Myron
  organization: Institute of Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina
– sequence: 20
  givenname: George M.
  surname: Shaw
  fullname: Shaw, George M.
  organization: Division of Hematology/Oncology, University of Alabama at Birmingham, 720 20th Street South, Kaul 816, Birmingham, Alabama 35294-0024
– sequence: 21
  givenname: John R.
  surname: Mascola
  fullname: Mascola, John R.
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, 40 Convent Drive, Bethesda, Maryland 20892
– sequence: 22
  givenname: Barton F.
  surname: Haynes
  fullname: Haynes, Barton F.
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 23
  givenname: David C.
  surname: Montefiori
  fullname: Montefiori, David C.
  organization: Duke Human Vaccine Institute and Departments of Surgery, Medicine, Immunology, and Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710
– sequence: 24
  givenname: Lynn
  surname: Morris
  fullname: Morris, Lynn
  organization: National Institute for Communicable Diseases, Private Bag X4, Sandringham 2131, Johannesburg
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24613186$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21849452$$D View this record in MEDLINE/PubMed
BookMark eNp1kctv1DAQxi1URLeFG2dkCSEupHj8inNBglWhiypAPCpuluM4Xa-ydoiTReWvx_soL4nT2Jrf983omxN0FGJwCD0EcgZA1fO3V4szIphkBcAdNANSqUII4EdoRgilhWDq6zE6SWlFCHAu-T10TEHxigs6Q6sPsbuxXQymw6_w3HUd_uhSH0NyCY8Rz7evYeMa_M5N42A6_8OMPgZ83vsx9hnyARv8aaqTG3Fs8cXiqoBiEVpnx6xahMZvfDOZLt1Hd9tc3INDPUVfXp9_nl8Ul-_fLOYvLwvLOYyFbSyry6ayUBrFgYCjta1MWZdEOmlFI2srJbSqZDU1riKibDmrZVsyoURt2Cl6sfftp3rtGuvCdm_dD35thhsdjdd_d4Jf6uu40QwqXgmZDZ4eDIb4bXJp1GufbI7GBBenpFUlFWNUbclHf476NeM23ww8OQAmWdO1gwnWp98cl8BgZ0T3nB1iSoNrtfXjLui8oe80EL09ts7H1rtj528WPftHdOv7H_zxHl_66-V3Pzht0lqvNl4rkTfOiCCU_QRTRrb6
CitedBy_id crossref_primary_10_1038_s41598_018_33390_2
crossref_primary_10_1128_JVI_01653_15
crossref_primary_10_1371_journal_pone_0077756
crossref_primary_10_1128_JVI_00734_12
crossref_primary_10_1038_nm_3598
crossref_primary_10_1128_JVI_01596_16
crossref_primary_10_1128_JVI_01246_19
crossref_primary_10_1111_imr_12501
crossref_primary_10_1111_imr_12502
crossref_primary_10_3390_v12020163
crossref_primary_10_1099_vir_0_043802_0
crossref_primary_10_1016_j_it_2014_08_007
crossref_primary_10_1038_s41577_022_00753_w
crossref_primary_10_1134_S0026893317060176
crossref_primary_10_1016_j_jim_2014_11_006
crossref_primary_10_1128_JVI_03090_15
crossref_primary_10_1172_JCI75894
crossref_primary_10_1038_s42003_018_0131_6
crossref_primary_10_1128_JVI_01077_17
crossref_primary_10_1371_journal_ppat_1010450
crossref_primary_10_1016_j_celrep_2019_12_091
crossref_primary_10_1128_JVI_01564_15
crossref_primary_10_1038_ni_3158
crossref_primary_10_1128_JVI_01161_13
crossref_primary_10_1371_journal_ppat_1007840
crossref_primary_10_1186_s12929_014_0079_x
crossref_primary_10_1089_aid_2015_0324
crossref_primary_10_3390_vaccines12010008
crossref_primary_10_1016_j_jconrel_2019_11_035
crossref_primary_10_1128_JVI_00401_17
crossref_primary_10_1038_s41467_023_42906_y
crossref_primary_10_1016_j_virol_2020_03_003
crossref_primary_10_1371_journal_pone_0194266
crossref_primary_10_1038_nature12053
crossref_primary_10_1371_journal_ppat_1004973
crossref_primary_10_1093_infdis_jiz008
crossref_primary_10_1038_srep46308
crossref_primary_10_1016_j_immuni_2016_03_006
crossref_primary_10_1038_nri3516
crossref_primary_10_1002_jctb_3796
crossref_primary_10_1016_j_jmb_2012_11_010
crossref_primary_10_1097_COH_0000000000000049
crossref_primary_10_1038_nature11519
crossref_primary_10_1016_j_jim_2013_06_001
crossref_primary_10_1016_j_virol_2016_10_026
crossref_primary_10_1186_s12977_016_0297_2
crossref_primary_10_1016_j_celrep_2015_12_017
crossref_primary_10_1038_mt_2016_123
crossref_primary_10_1097_QAD_0000000000001038
crossref_primary_10_1371_journal_ppat_1006986
crossref_primary_10_1128_JVI_00599_12
crossref_primary_10_1016_j_immuni_2012_08_012
crossref_primary_10_1038_srep46557
crossref_primary_10_3390_ijms25137200
crossref_primary_10_1073_pnas_1217207109
crossref_primary_10_1128_MMBR_00024_15
crossref_primary_10_1038_nature13808
crossref_primary_10_3389_fmicb_2018_01216
crossref_primary_10_1016_j_vaccine_2011_11_089
crossref_primary_10_1371_journal_pone_0037648
crossref_primary_10_1371_journal_pcbi_1003973
crossref_primary_10_1128_JVI_03527_14
crossref_primary_10_3390_v10040167
crossref_primary_10_1371_journal_ppat_1003738
crossref_primary_10_1016_j_chom_2019_09_016
crossref_primary_10_1128_JVI_06201_11
crossref_primary_10_1128_JVI_00129_15
crossref_primary_10_1016_j_tim_2014_12_007
crossref_primary_10_1097_QAD_0000000000001724
crossref_primary_10_1371_journal_pone_0101863
crossref_primary_10_1371_journal_ppat_1005369
crossref_primary_10_1002_cbic_202200061
crossref_primary_10_1016_j_jaci_2014_04_025
crossref_primary_10_1038_nm_2985
crossref_primary_10_1371_journal_ppat_1011359
crossref_primary_10_1128_JVI_02737_12
crossref_primary_10_1128_JVI_07163_11
crossref_primary_10_1371_journal_ppat_1010945
crossref_primary_10_1016_j_immuni_2019_04_014
crossref_primary_10_1128_JVI_01737_19
crossref_primary_10_1016_j_antiviral_2015_08_004
crossref_primary_10_1128_CVI_00717_15
crossref_primary_10_1093_infdis_jiab629
crossref_primary_10_1038_s41598_019_40175_8
crossref_primary_10_1126_sciimmunol_aal2200
crossref_primary_10_1128_JVI_01265_15
crossref_primary_10_1016_j_cell_2014_06_022
crossref_primary_10_1016_j_virol_2014_03_015
crossref_primary_10_1089_aid_2015_0135
crossref_primary_10_1371_journal_pcbi_1007056
crossref_primary_10_1016_j_celrep_2018_03_082
crossref_primary_10_1097_COH_0000000000000359
crossref_primary_10_1128_JVI_03635_14
crossref_primary_10_1016_j_chom_2015_08_006
crossref_primary_10_1016_j_coi_2015_05_007
crossref_primary_10_1016_j_chom_2014_08_006
crossref_primary_10_1186_1743_422X_10_347
crossref_primary_10_1371_journal_pone_0113463
crossref_primary_10_1128_JVI_02261_17
crossref_primary_10_1371_journal_pone_0193773
crossref_primary_10_1016_j_jim_2017_12_003
crossref_primary_10_1128_JVI_00426_12
crossref_primary_10_1371_journal_ppat_1002634
crossref_primary_10_1128_spectrum_01634_22
crossref_primary_10_1021_acs_jproteome_0c00484
crossref_primary_10_4049_jimmunol_1601640
crossref_primary_10_1038_s41586_024_08500_y
crossref_primary_10_1002_eji_201242974
crossref_primary_10_1097_QAI_0b013e31829a3985
crossref_primary_10_1128_JVI_00335_16
crossref_primary_10_1089_aid_2020_0299
crossref_primary_10_3390_ijms24109077
crossref_primary_10_1084_jem_20121977
crossref_primary_10_1128_JVI_00878_18
crossref_primary_10_1016_j_tim_2012_08_011
crossref_primary_10_1186_s12977_018_0443_0
crossref_primary_10_1093_infdis_jis671
crossref_primary_10_1126_scitranslmed_3007736
crossref_primary_10_1016_j_molmed_2019_01_007
crossref_primary_10_1093_infdis_jiy008
crossref_primary_10_1371_journal_ppat_1006148
crossref_primary_10_1016_j_virol_2020_06_016
crossref_primary_10_1111_imm_12985
crossref_primary_10_3389_fimmu_2017_01154
crossref_primary_10_1038_ncomms15711
crossref_primary_10_1097_COH_0000000000000057
crossref_primary_10_1128_JVI_03424_12
crossref_primary_10_1371_journal_pone_0119608
crossref_primary_10_1016_j_chom_2018_04_018
crossref_primary_10_1128_CVI_00231_17
crossref_primary_10_1111_imr_12509
crossref_primary_10_1097_COH_0b013e328361d178
crossref_primary_10_1371_journal_pone_0089648
crossref_primary_10_1111_imr_12505
crossref_primary_10_1038_s41467_023_36907_0
crossref_primary_10_1128_JVI_01705_14
crossref_primary_10_1097_QAD_0000000000000308
crossref_primary_10_1128_JVI_03608_14
crossref_primary_10_1111_imr_12511
crossref_primary_10_1128_JVI_00230_16
crossref_primary_10_1128_JVI_01552_17
crossref_primary_10_1172_JCI73441
crossref_primary_10_1038_nature11544
crossref_primary_10_1126_sciimmunol_aag0851
crossref_primary_10_1128_JVI_01495_18
crossref_primary_10_1371_journal_ppat_1005042
crossref_primary_10_1038_nbt_2197
crossref_primary_10_1128_JVI_03070_12
Cites_doi 10.1007/978-1-4615-0065-0_13
10.1128/jvi.70.3.1651-1667.1996
10.1128/JVI.79.16.10108-10125.2005
10.1128/jvi.70.2.1100-1108.1996
10.1128/JVI.02588-06
10.1016/j.virol.2007.01.015
10.1128/JVI.00758-09
10.1128/JVI.77.19.10557-10565.2003
10.1371/journal.pone.0004505
10.2174/138161207779313632
10.1128/JVI.02617-09
10.1128/jvi.71.4.2799-2809.1997
10.1016/j.jviromet.2009.02.014
10.1084/jem.182.1.185
10.1128/JVI.01379-08
10.1128/JVI.02036-08
10.1128/JVI.02187-07
10.1128/JVI.76.15.7760-7776.2002
10.1371/journal.ppat.1000594
10.1128/JVI.01992-08
10.1128/JVI.02658-10
10.1126/science.1083182
10.1128/JVI.01359-09
10.1128/JVI.02749-06
10.1016/j.virol.2009.10.044
10.1038/nm.1974
10.1073/pnas.0630530100
10.1128/MMBR.00020-07
10.1146/annurev-immunol-030409-101256
10.1128/JVI.05045-11
10.1128/JVI.78.23.13232-13252.2004
10.1073/pnas.0912381107
10.1089/08892220260387959
10.1084/jem.20042510
10.1128/JVI.00198-11
10.1371/journal.pone.0016074
10.1089/aid.1994.10.1629
10.1128/JVI.00257-07
10.1128/jvi.71.4.2779-2785.1997
10.1128/JVI.77.10.5829-5836.2003
10.1128/JVI.79.8.5232-5237.2005
10.1038/nature07930
10.1038/nri2674
10.1016/j.coi.2010.02.012
10.1128/JVI.01730-06
10.1128/JVI.77.10.5678-5684.2003
10.1371/journal.ppat.1001251
10.1371/journal.pcbi.1000955
10.1038/nm833
10.1128/JVI.02187-10
10.1128/JVI.00552-10
10.1016/j.vaccine.2009.07.085
10.1371/journal.ppat.1000598
10.1016/j.virol.2007.03.007
10.1016/S0969-2126(03)00011-X
10.1038/nm0204-133
10.1056/NEJMra1011874
10.1128/jvi.67.11.6642-6647.1993
10.1126/science.1192819
10.1126/science.1207532
10.1038/nature05818
10.1128/jvi.71.2.1657-1661.1997
10.1371/journal.pone.0010254
10.1126/science.1178746
10.1016/j.virol.2007.05.024
10.1128/JVI.01482-09
10.1128/JVI.00563-11
10.1126/science.7973652
10.1371/journal.pmed.0050009
10.3233/HAB-2005-143-407
10.1128/JVI.80.6.3030-3041.2006
10.1371/journal.ppat.1000433
10.1128/JVI.00110-09
10.1371/journal.pone.0008805
10.1038/nm0403-393
10.1038/72318
10.1128/JVI.76.14.7293-7305.2002
10.1038/nm1624
10.1006/jmbi.1993.1203
10.1128/JVI.00757-08
10.1128/JVI.02108-09
10.1038/ni0304-233
10.1128/JVI.00239-07
10.1128/JVI.75.17.8340-8347.2001
10.1016/S0264-410X(02)00068-3
10.1128/JVI.02161-07
10.1128/JVI.00424-07
10.1097/COH.0b013e32832e06fe
10.1128/JVI.75.22.10892-10905.2001
10.1126/science.1111781
10.1128/JVI.76.14.7306-7321.2002
10.1128/JVI.02631-08
10.1371/journal.ppat.1001028
10.1128/JVI.00790-10
10.1128/JVI.01762-08
10.1126/science.1161121
10.1128/JVI.01708-08
10.1126/science.1187659
10.1038/nature01470
10.1016/j.virol.2008.04.045
10.1128/JVI.80.5.2515-2528.2006
10.1073/pnas.84.8.2479
10.1089/aid.1998.14.1129
10.1128/JVI.01743-08
10.1128/JVI.75.4.1990-1995.2001
10.1016/j.virol.2007.04.033
10.1128/JVI.01272-09
ContentType Journal Article
Copyright 2015 INIST-CNRS
Copyright © 2011, American Society for Microbiology. All Rights Reserved. 2011 American Society for Microbiology
Copyright_xml – notice: 2015 INIST-CNRS
– notice: Copyright © 2011, American Society for Microbiology. All Rights Reserved. 2011 American Society for Microbiology
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1128/JVI.05363-11
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
EndPage 11519
ExternalDocumentID PMC3194956
21849452
24613186
10_1128_JVI_05363_11
jvi_85_21_11502
Genre Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: U19 AI067854
– fundername: NIAID NIH HHS
  grantid: AI067854-05
– fundername: NIAID NIH HHS
  grantid: AI58C1-0763
– fundername: Intramural NIH HHS
– fundername: NIAID NIH HHS
  grantid: R01 AI093278
– fundername: NIAID NIH HHS
  grantid: U01 AI067854
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAFWJ
AAGFI
AAYJJ
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
ADXHL
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
D0S
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c441t-cdc3b7d9c17a84101e2bc9a7b706e6c5d6bc661f873b2ae9057f43b6f73585ba3
ISSN 0022-538X
1098-5514
IngestDate Thu Aug 21 14:12:31 EDT 2025
Thu Sep 04 20:15:42 EDT 2025
Mon Jul 21 06:01:21 EDT 2025
Mon Jul 21 09:14:14 EDT 2025
Thu Apr 24 22:51:50 EDT 2025
Tue Jul 01 01:02:09 EDT 2025
Wed May 18 15:26:05 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Keywords Infection
Immunopathology
Antigenic determinant
Viral disease
AIDS
B-Lymphocyte
Immune deficiency
Neutralizing antibody
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c441t-cdc3b7d9c17a84101e2bc9a7b706e6c5d6bc661f873b2ae9057f43b6f73585ba3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G.D.T., J.M.B., and L.M. contributed equally to this work.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/3194956
PMID 21849452
PQID 896833286
PQPubID 23479
PageCount 18
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3194956
proquest_miscellaneous_896833286
pubmed_primary_21849452
crossref_citationtrail_10_1128_JVI_05363_11
highwire_asm_jvi_85_21_11502
crossref_primary_10_1128_JVI_05363_11
pascalfrancis_primary_24613186
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2011-11-01
PublicationDateYYYYMMDD 2011-11-01
PublicationDate_xml – month: 11
  year: 2011
  text: 2011-11-01
  day: 01
PublicationDecade 2010
PublicationPlace Washington, DC
PublicationPlace_xml – name: Washington, DC
– name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of Virology
PublicationTitleAlternate J Virol
PublicationYear 2011
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_3_96_2
e_1_3_3_50_2
e_1_3_3_77_2
D'Amelio R. (e_1_3_3_24_2) 1992; 5
e_1_3_3_117_2
e_1_3_3_16_2
e_1_3_3_39_2
e_1_3_3_12_2
e_1_3_3_58_2
e_1_3_3_35_2
e_1_3_3_92_2
e_1_3_3_113_2
e_1_3_3_54_2
Walker L. M. (e_1_3_3_111_2) 2010
e_1_3_3_31_2
e_1_3_3_73_2
e_1_3_3_61_2
e_1_3_3_88_2
e_1_3_3_5_2
e_1_3_3_9_2
e_1_3_3_27_2
e_1_3_3_109_2
e_1_3_3_23_2
e_1_3_3_69_2
e_1_3_3_120_2
e_1_3_3_46_2
e_1_3_3_80_2
e_1_3_3_65_2
e_1_3_3_42_2
e_1_3_3_84_2
e_1_3_3_101_2
e_1_3_3_76_2
e_1_3_3_99_2
e_1_3_3_116_2
Bibollet-Ruche F. (e_1_3_3_4_2) 2006
e_1_3_3_19_2
e_1_3_3_38_2
e_1_3_3_15_2
e_1_3_3_34_2
e_1_3_3_57_2
e_1_3_3_91_2
e_1_3_3_11_2
e_1_3_3_30_2
e_1_3_3_53_2
e_1_3_3_72_2
e_1_3_3_95_2
e_1_3_3_112_2
e_1_3_3_60_2
e_1_3_3_87_2
e_1_3_3_8_2
e_1_3_3_104_2
e_1_3_3_49_2
e_1_3_3_108_2
e_1_3_3_26_2
e_1_3_3_45_2
e_1_3_3_68_2
e_1_3_3_22_2
e_1_3_3_41_2
e_1_3_3_64_2
e_1_3_3_83_2
e_1_3_3_100_2
e_1_3_3_75_2
e_1_3_3_71_2
e_1_3_3_98_2
e_1_3_3_79_2
e_1_3_3_115_2
e_1_3_3_119_2
e_1_3_3_18_2
e_1_3_3_37_2
e_1_3_3_90_2
e_1_3_3_14_2
e_1_3_3_56_2
e_1_3_3_33_2
e_1_3_3_94_2
e_1_3_3_10_2
e_1_3_3_52_2
e_1_3_3_40_2
e_1_3_3_86_2
Tomaras G. D. (e_1_3_3_105_2) 2003
e_1_3_3_107_2
e_1_3_3_7_2
e_1_3_3_29_2
e_1_3_3_48_2
e_1_3_3_25_2
e_1_3_3_67_2
e_1_3_3_44_2
e_1_3_3_82_2
e_1_3_3_103_2
e_1_3_3_3_2
e_1_3_3_21_2
e_1_3_3_63_2
e_1_3_3_122_2
e_1_3_3_51_2
e_1_3_3_74_2
e_1_3_3_97_2
e_1_3_3_70_2
e_1_3_3_78_2
e_1_3_3_118_2
e_1_3_3_17_2
e_1_3_3_13_2
e_1_3_3_36_2
e_1_3_3_59_2
e_1_3_3_110_2
e_1_3_3_32_2
e_1_3_3_55_2
e_1_3_3_93_2
e_1_3_3_114_2
e_1_3_3_62_2
e_1_3_3_85_2
e_1_3_3_89_2
e_1_3_3_6_2
e_1_3_3_106_2
e_1_3_3_28_2
e_1_3_3_47_2
e_1_3_3_121_2
e_1_3_3_2_2
e_1_3_3_20_2
e_1_3_3_43_2
e_1_3_3_66_2
e_1_3_3_81_2
e_1_3_3_102_2
References_xml – ident: e_1_3_3_95_2
  doi: 10.1007/978-1-4615-0065-0_13
– ident: e_1_3_3_34_2
  doi: 10.1128/jvi.70.3.1651-1667.1996
– ident: e_1_3_3_56_2
  doi: 10.1128/JVI.79.16.10108-10125.2005
– ident: e_1_3_3_108_2
  doi: 10.1128/jvi.70.2.1100-1108.1996
– volume-title: Conf. Retroviruses Opportunistic Infect. (CROI)
  year: 2003
  ident: e_1_3_3_105_2
– ident: e_1_3_3_78_2
  doi: 10.1128/JVI.02588-06
– ident: e_1_3_3_17_2
  doi: 10.1016/j.virol.2007.01.015
– ident: e_1_3_3_42_2
  doi: 10.1128/JVI.00758-09
– ident: e_1_3_3_54_2
  doi: 10.1128/JVI.77.19.10557-10565.2003
– ident: e_1_3_3_31_2
  doi: 10.1371/journal.pone.0004505
– ident: e_1_3_3_83_2
  doi: 10.2174/138161207779313632
– ident: e_1_3_3_85_2
  doi: 10.1128/JVI.02617-09
– ident: e_1_3_3_7_2
  doi: 10.1128/jvi.71.4.2799-2809.1997
– ident: e_1_3_3_61_2
  doi: 10.1016/j.jviromet.2009.02.014
– ident: e_1_3_3_92_2
  doi: 10.1084/jem.182.1.185
– ident: e_1_3_3_32_2
  doi: 10.1128/JVI.01379-08
– ident: e_1_3_3_90_2
  doi: 10.1128/JVI.02036-08
– ident: e_1_3_3_72_2
  doi: 10.1128/JVI.02187-07
– ident: e_1_3_3_97_2
  doi: 10.1128/JVI.76.15.7760-7776.2002
– ident: e_1_3_3_87_2
  doi: 10.1371/journal.ppat.1000594
– ident: e_1_3_3_59_2
  doi: 10.1128/JVI.01992-08
– ident: e_1_3_3_107_2
– ident: e_1_3_3_73_2
  doi: 10.1128/JVI.02658-10
– ident: e_1_3_3_15_2
  doi: 10.1126/science.1083182
– ident: e_1_3_3_38_2
  doi: 10.1128/JVI.01359-09
– ident: e_1_3_3_27_2
  doi: 10.1128/JVI.02749-06
– ident: e_1_3_3_77_2
  doi: 10.1016/j.virol.2009.10.044
– ident: e_1_3_3_47_2
  doi: 10.1038/nm.1974
– ident: e_1_3_3_84_2
  doi: 10.1073/pnas.0630530100
– ident: e_1_3_3_70_2
  doi: 10.1128/MMBR.00020-07
– ident: e_1_3_3_64_2
  doi: 10.1146/annurev-immunol-030409-101256
– ident: e_1_3_3_11_2
  doi: 10.1128/JVI.05045-11
– ident: e_1_3_3_9_2
  doi: 10.1128/JVI.78.23.13232-13252.2004
– ident: e_1_3_3_101_2
  doi: 10.1073/pnas.0912381107
– ident: e_1_3_3_117_2
  doi: 10.1089/08892220260387959
– ident: e_1_3_3_26_2
  doi: 10.1084/jem.20042510
– ident: e_1_3_3_37_2
  doi: 10.1128/JVI.00198-11
– ident: e_1_3_3_43_2
  doi: 10.1371/journal.pone.0016074
– ident: e_1_3_3_44_2
  doi: 10.1089/aid.1994.10.1629
– ident: e_1_3_3_30_2
– ident: e_1_3_3_86_2
  doi: 10.1128/JVI.00257-07
– ident: e_1_3_3_33_2
  doi: 10.1128/jvi.71.4.2779-2785.1997
– ident: e_1_3_3_2_2
  doi: 10.1128/JVI.77.10.5829-5836.2003
– ident: e_1_3_3_36_2
  doi: 10.1128/JVI.79.8.5232-5237.2005
– ident: e_1_3_3_55_2
– ident: e_1_3_3_96_2
  doi: 10.1038/nature07930
– ident: e_1_3_3_66_2
  doi: 10.1038/nri2674
– ident: e_1_3_3_110_2
  doi: 10.1016/j.coi.2010.02.012
– ident: e_1_3_3_57_2
  doi: 10.1128/JVI.01730-06
– ident: e_1_3_3_6_2
  doi: 10.1128/JVI.77.10.5678-5684.2003
– ident: e_1_3_3_67_2
  doi: 10.1371/journal.ppat.1001251
– ident: e_1_3_3_35_2
  doi: 10.1371/journal.pcbi.1000955
– volume-title: Keystone Symp. X6, HIV Vaccines
  year: 2006
  ident: e_1_3_3_4_2
– ident: e_1_3_3_109_2
  doi: 10.1038/nm833
– ident: e_1_3_3_75_2
  doi: 10.1128/JVI.02187-10
– ident: e_1_3_3_28_2
  doi: 10.1128/JVI.00552-10
– ident: e_1_3_3_91_2
  doi: 10.1016/j.vaccine.2009.07.085
– ident: e_1_3_3_74_2
  doi: 10.1371/journal.ppat.1000598
– ident: e_1_3_3_23_2
– ident: e_1_3_3_68_2
– ident: e_1_3_3_81_2
  doi: 10.1016/j.virol.2007.03.007
– ident: e_1_3_3_100_2
  doi: 10.1016/S0969-2126(03)00011-X
– ident: e_1_3_3_122_2
  doi: 10.1038/nm0204-133
– ident: e_1_3_3_18_2
  doi: 10.1056/NEJMra1011874
– ident: e_1_3_3_76_2
  doi: 10.1128/jvi.67.11.6642-6647.1993
– ident: e_1_3_3_120_2
  doi: 10.1126/science.1192819
– ident: e_1_3_3_115_2
  doi: 10.1126/science.1207532
– ident: e_1_3_3_93_2
  doi: 10.1038/nature05818
– ident: e_1_3_3_16_2
  doi: 10.1128/jvi.71.2.1657-1661.1997
– ident: e_1_3_3_52_2
  doi: 10.1371/journal.pone.0010254
– ident: e_1_3_3_112_2
  doi: 10.1126/science.1178746
– ident: e_1_3_3_99_2
  doi: 10.1016/j.virol.2007.05.024
– ident: e_1_3_3_29_2
  doi: 10.1128/JVI.01482-09
– ident: e_1_3_3_39_2
  doi: 10.1128/JVI.00563-11
– ident: e_1_3_3_14_2
  doi: 10.1126/science.7973652
– ident: e_1_3_3_10_2
  doi: 10.1371/journal.pmed.0050009
– ident: e_1_3_3_22_2
  doi: 10.3233/HAB-2005-143-407
– ident: e_1_3_3_119_2
  doi: 10.1128/JVI.80.6.3030-3041.2006
– ident: e_1_3_3_118_2
– ident: e_1_3_3_48_2
  doi: 10.1371/journal.ppat.1000433
– ident: e_1_3_3_103_2
  doi: 10.1128/JVI.00110-09
– ident: e_1_3_3_19_2
  doi: 10.1371/journal.pone.0008805
– ident: e_1_3_3_51_2
– ident: e_1_3_3_63_2
  doi: 10.1038/nm0403-393
– ident: e_1_3_3_65_2
  doi: 10.1038/72318
– ident: e_1_3_3_88_2
  doi: 10.1128/JVI.76.14.7293-7305.2002
– volume-title: AIDS Vaccine 10 Conf.
  year: 2010
  ident: e_1_3_3_111_2
– ident: e_1_3_3_58_2
  doi: 10.1038/nm1624
– ident: e_1_3_3_3_2
  doi: 10.1006/jmbi.1993.1203
– ident: e_1_3_3_12_2
  doi: 10.1128/JVI.00757-08
– ident: e_1_3_3_98_2
  doi: 10.1128/JVI.02108-09
– ident: e_1_3_3_60_2
– ident: e_1_3_3_13_2
  doi: 10.1038/ni0304-233
– ident: e_1_3_3_41_2
  doi: 10.1128/JVI.00239-07
– ident: e_1_3_3_82_2
  doi: 10.1128/JVI.75.17.8340-8347.2001
– ident: e_1_3_3_62_2
  doi: 10.1016/S0264-410X(02)00068-3
– ident: e_1_3_3_50_2
– ident: e_1_3_3_40_2
  doi: 10.1128/JVI.02161-07
– ident: e_1_3_3_53_2
  doi: 10.1128/JVI.00424-07
– ident: e_1_3_3_5_2
  doi: 10.1097/COH.0b013e32832e06fe
– ident: e_1_3_3_121_2
  doi: 10.1128/JVI.75.22.10892-10905.2001
– ident: e_1_3_3_46_2
  doi: 10.1126/science.1111781
– ident: e_1_3_3_94_2
  doi: 10.1128/JVI.76.14.7306-7321.2002
– ident: e_1_3_3_102_2
  doi: 10.1128/JVI.02631-08
– ident: e_1_3_3_113_2
  doi: 10.1371/journal.ppat.1001028
– ident: e_1_3_3_79_2
  doi: 10.1128/JVI.00790-10
– volume: 5
  start-page: 930
  year: 1992
  ident: e_1_3_3_24_2
  article-title: Spectrotype of anti-gp120 antibodies remains stable during the course of HIV disease
  publication-title: J. Acquir. Immune Defic. Syndr
– ident: e_1_3_3_8_2
  doi: 10.1128/JVI.01762-08
– ident: e_1_3_3_89_2
  doi: 10.1126/science.1161121
– ident: e_1_3_3_106_2
  doi: 10.1128/JVI.01708-08
– ident: e_1_3_3_116_2
  doi: 10.1126/science.1187659
– ident: e_1_3_3_114_2
  doi: 10.1038/nature01470
– ident: e_1_3_3_20_2
  doi: 10.1016/j.virol.2008.04.045
– ident: e_1_3_3_71_2
  doi: 10.1128/JVI.80.5.2515-2528.2006
– ident: e_1_3_3_80_2
  doi: 10.1073/pnas.84.8.2479
– ident: e_1_3_3_69_2
– ident: e_1_3_3_104_2
  doi: 10.1089/aid.1998.14.1129
– ident: e_1_3_3_25_2
  doi: 10.1128/JVI.01743-08
– ident: e_1_3_3_45_2
  doi: 10.1128/JVI.75.4.1990-1995.2001
– ident: e_1_3_3_21_2
  doi: 10.1016/j.virol.2007.04.033
– ident: e_1_3_3_49_2
  doi: 10.1128/JVI.01272-09
SSID ssj0014464
Score 2.44594
Snippet Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley...
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 11502
SubjectTerms Antibodies, Neutralizing - blood
B-Lymphocytes - immunology
Biological and medical sciences
Epitopes, B-Lymphocyte - immunology
Fundamental and applied biological sciences. Psychology
HIV Antibodies - blood
HIV Envelope Protein gp120 - immunology
HIV Envelope Protein gp41 - immunology
HIV Infections - immunology
HIV-1 - immunology
Humans
Microbiology
Miscellaneous
Pathogenesis and Immunity
Virology
Title Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals
URI http://jvi.asm.org/content/85/21/11502.abstract
https://www.ncbi.nlm.nih.gov/pubmed/21849452
https://www.proquest.com/docview/896833286
https://pubmed.ncbi.nlm.nih.gov/PMC3194956
Volume 85
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj9JAFJ7gGhNfjHdZ18086NOkFdrSy6MgLmyCMcoS3pqZoY1doSVcNln_nf_Mc2Z6JaxRXxooQztwvp7bfOcMIW8XHg8Cx40NsCbCQI_YEJ4QhnSsSMSy4_MYV3Qnn93RlXM5781brV811tJ-J0z582hdyf9IFc6BXLFK9h8kW14UTsBrkC8cQcJw_CsZf8mWt3Kpcnl9NsAs3FdNedV9G3AzTiQ0LkCV7VVGQ9dcsuEanuO1omIxrnRHpAgBo_EMYr2x4mdFSBMuirW2d_iws2TTSMurDHvC2UeTTbMV3_CKoIhsXDYxWT9Ji7VkRRmBKXwz2cWmIvMMVyvOpiYbgFP_o5GWQF5cIy1RrjfVyaeTpGouVVfKGA_baodhMElaD2ObU3Tm6opa7-2TA1LXVedqF91a67hBsLDI4XI2NkHbuLahNXsNG-uVAgdGuoGjm-k2u3IfWMuSw3h9k4R-L7S6obr7PXLf8jzFFLiYlywjjLadomE9_sai9sLy39cnpXpS6xk0HaSiaTVydvkWHttY77dyLCA65PXWHKXpY_IoRwf9oOH6hLSi9Cl5oPc8vX1GrivQ0j5F0NIStHSX0RK0tAlaWoCWJinlVIOWZjFtgpbWQPucXH0aTgcjI9_wA1SD090ZciFt4S0C2fW474CxiCwhA-4Jr-NGruwtXCHBn4x9zxYWjwKINWLHFm7s2RD1Cm6_ICdplkavCLV9ITt2DxRUF7s9OAKu7EQQC3XwjBBtwop_OZR5N3zclGUZqqjY8kMQT6jEA2_b5F05eq27wNwx7qwQWMi3q_AAI21y3hBieS1s6gjG1W0TWkg1BDWPa3c8jbL9NvQD17dtC4e81EKuvpwDp028hvjLAdhBvvlJmnxXneTB_mKC5PTP035NHlZP-Bk52W320RtwxXfiXIH9Nxu937Q
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polyclonal+B+Cell+Responses+to+Conserved+Neutralization+Epitopes+in+a+Subset+of+HIV-1-Infected+Individuals&rft.jtitle=Journal+of+Virology&rft.au=Georgia+D.+Tomaras&rft.au=James+M.+Binley&rft.au=Elin+S.+Gray&rft.au=Emma+T.+Crooks&rft.date=2011-11-01&rft.pub=American+Society+for+Microbiology&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=85&rft.issue=21&rft.spage=11502&rft_id=info:doi/10.1128%2FJVI.05363-11&rft_id=info%3Apmid%2F21849452&rft.externalDBID=n%2Fa&rft.externalDocID=jvi_85_21_11502
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon